News about FDA, drug, and Alzheimer

Yesterday, the @US_FDA Advisory Committee unanimously endorsed the efficacy and clinical benefit of donanemab. If approval is granted by the FDA, donanemab will be the second traditional approval of an Alzheimer’s treatment that changes the underlying course of the disease, and… pic.twitter.com/1w198vVc3A

We welcome and celebrate the @US_FDA Advisory Committee’s unanimous endorsement of the efficacy and clinical benefit of donanemab as part of the treatment’s regulatory review process. Read our statement. www.alz.org/news/2024/fda-advisory-committee-donanemab-efficacy

Today, an #FDA Advisory Committee endorsed #donanemab. If approved, this would be the 2nd disease-modifying drug for #Alzheimer's to receive full approval, expanding the arsenal of available drugs needed to treat Alzheimer’s with #CombinationTherapy: bit.ly/3yTcJ1N pic.twitter.com/mTkLQn4jjE

"FDA officials shouldn’t let perfection get in the way of progress. Anti-amyloids are fairly safe, modestly effective, and the only disease-modifying drugs currently available," @a_hfillit speaks to the FDA ad comm and the impact of today's vote w/ @WSJ: on.wsj.com/3yUoAN7. pic.twitter.com/YwJyncDLqk